314 institutions hold shares in Coherus BioSciences Inc. (CHRS), with 1.17M shares held by insiders accounting for 1.62% while institutional investors hold 127.71% of the company’s shares. The shares outstanding are 71.65M, and float is at 64.13M with Short Float at 20.87%. Institutions hold 125.64% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Blackrock Inc. with over 10.53 million shares valued at $182.98 million. The investor’s holdings represent 14.61% of the CHRS Shares outstanding. As of Dec 30, 2020, the second largest holder is Temasek Holdings (Private) Limited with 7.38 million shares valued at $128.28 million to account for 10.24% of the shares outstanding. The other top investors are JP Morgan Chase & Company which holds 4.95 million shares representing 6.88% and valued at over $86.09 million, while AllianceBernstein, L.P. holds 6.53% of the shares totaling 4.7 million with a market value of $81.76 million.
Coherus BioSciences Inc. (NASDAQ: CHRS) is -6.56% lower on its value in year-to-date trading and has touched a low of $10.86 and a high of $22.22 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CHRS stock was last observed hovering at around $16.37 in the last trading session, with the day’s loss setting it -0.13% off its average median price target of $30.00 for the next 12 months. It is also 53.6% off the consensus price target high of $35.00 offered by 10 analysts, but current levels are 14.53% higher than the price target low of $19.00 for the same period.
Currently trading at $16.24, the stock is -11.87% and -9.43% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.18 million and changing -0.79% at the moment leaves the stock -10.06% off its SMA200. CHRS registered -25.09% loss for a year compared to 6-month loss of -14.53%. The firm has a 50-day simple moving average (SMA 50) of $18.16 and a 200-day simple moving average (SMA200) of $18.18.
The stock witnessed a -11.40% gain in the last 1 month and extending the period to 3 months gives it a -9.38%, and is -6.88% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.72% over the week and 7.26% over the month.
Coherus BioSciences Inc. (CHRS) has around 306 employees, a market worth around $1.14B and $489.30M in sales. Current P/E ratio is 8.05 and Fwd P/E is 14.98. Profit margin for the company is 33.10%. Distance from 52-week low is 49.52% and -26.90% from its 52-week high. The company has generated returns on investments over the last 12 months (37.00%).
Coherus BioSciences Inc. (CHRS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Coherus BioSciences Inc. (CHRS) is a “Buy”. 10 analysts offering their recommendations for the stock have an average rating of 1.90, where 1 rate it as a Hold and 1 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Coherus BioSciences Inc. is expected to release its quarterly report on 05/13/2021 and quarterly earnings per share for the current quarter are estimated at $0.23 with sales reaching $115.12M over the same period.The EPS is expected to grow by 138.10% this year, but quarterly earnings will post 35.00% year-over-year. Quarterly sales are estimated to shrink -7.10% in year-over-year returns.
Coherus BioSciences Inc. (CHRS) Insider Activity
The most recent transaction is an insider sale by Anicetti Vincent R, the company’s Chief Operating Officer. SEC filings show that Anicetti Vincent R sold 2,488 shares of the company’s common stock on Feb 17 at a price of $17.45 per share for a total of $43418.0. Following the sale, the insider now owns 59739.0 shares.
Coherus BioSciences Inc. disclosed in a document filed with the SEC on Feb 01 that Viret Jean-Frederic (Chief Financial Officer) sold a total of 7,402 shares of the company’s common stock. The trade occurred on Feb 01 and was made at $21.55 per share for $0.16 million. Following the transaction, the insider now directly holds 61295.0 shares of the CHRS stock.
Still, SEC filings show that on Jan 25, Viret Jean-Frederic (Chief Financial Officer) disposed off 46,144 shares at an average price of $19.95 for $0.92 million. The insider now directly holds 61,295 shares of Coherus BioSciences Inc. (CHRS).
Coherus BioSciences Inc. (CHRS): Who are the competitors?
The company’s main competitors (and peers) include Affimed N.V. (AFMD) that is trading 110.80% up over the past 12 months. Repligen Corporation (RGEN) is 122.75% up on the 1-year trading charts. Short interest in the company’s stock has fallen -15.68% from the last report on Dec 30, 2020 to stand at a total of 15.49 million short shares sold with a short interest ratio of 9.64.